MedPath

1,2-Benzodiazepine

Generic Name
1,2-Benzodiazepine
Drug Type
Small Molecule
Chemical Formula
C9H8N2
CAS Number
264-60-8
Unique Ingredient Identifier
M0Q7802G2B
Background

Benzodiazepine is under investigation for the prevention of Delirium and C.Surgical Procedure; Cardiac. Benzodiazepine has been investigated for the treatment of Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.

Clinical Trials
Related News

Maternal and Neonatal Outcomes Following Exposure to Benzodiazepines During Pregnancy

Completed
Conditions
Pregnancy Related
Benzodiazepines Causing Adverse Effects in Therapeutic Use
Congenital Anomaly
Interventions
First Posted Date
2021-04-23
Last Posted Date
2022-03-07
Lead Sponsor
Sungkyunkwan University
Target Recruit Count
3094227
Registration Number
NCT04856436
Locations
🇰🇷

Sungkyunkwan University, Suwon, Gyeonggi-do, Korea, Republic of

Benzodiazepines in Opiate Replacement Therapy

Completed
Conditions
Substance-Related Disorders
Interventions
First Posted Date
2020-11-10
Last Posted Date
2023-03-09
Lead Sponsor
University of Stirling
Target Recruit Count
46899
Registration Number
NCT04622995
Locations
🇬🇧

NHS Scotland, Edinburgh, Scotland, United Kingdom

Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free)

Phase 1
Completed
Conditions
Post-operative Delirium
Interventions
First Posted Date
2017-02-15
Last Posted Date
2018-10-16
Lead Sponsor
McMaster University
Target Recruit Count
480
Registration Number
NCT03053869
Locations
🇨🇦

St. Boniface Hospital, Winnipeg, Manitoba, Canada

🇨🇦

Dr Summer Syed, Hamilton, Ontario, Canada

Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia

Completed
Conditions
Schizophrenia
Schizoaffective Disorder
Interventions
Drug: Mood stabilizer
Drug: Antipsychotic
First Posted Date
2016-05-18
Last Posted Date
2024-05-01
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
81921
Registration Number
NCT02775864

Decreasing the Incidence of Delirium After Cardiac Surgery

Phase 4
Withdrawn
Conditions
C.Surgical Procedure; Cardiac
Delirium
Interventions
First Posted Date
2014-04-22
Last Posted Date
2018-06-12
Lead Sponsor
University of California, Los Angeles
Registration Number
NCT02119806
Locations
🇺🇸

Ronald Reagan UCLA Medical Center, Department of Anesthesiology, Los Angeles, California, United States

WEUKBRE5559: IMI PROTECT: Benzodiazepines & Fracture

Completed
Conditions
Anxiety Disorders
Interventions
First Posted Date
2012-04-30
Last Posted Date
2014-07-08
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
1
Registration Number
NCT01587833

IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation

Phase 4
Completed
Conditions
Psychomotor Agitation
Acute Disease
Interventions
First Posted Date
2010-01-15
Last Posted Date
2016-02-09
Lead Sponsor
Janssen Cilag N.V./S.A.
Target Recruit Count
56
Registration Number
NCT01050478

Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons

Phase 4
Completed
Conditions
Adverse Effects
First Posted Date
2008-07-01
Last Posted Date
2012-03-27
Lead Sponsor
Minamihanno Hospital
Target Recruit Count
30
Registration Number
NCT00707915
Locations
🇯🇵

Minamihanno Hospital, Hannou, Saitama, Japan

A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder

Phase 3
Completed
Conditions
Anxiety Disorder
First Posted Date
2005-04-01
Last Posted Date
2008-01-09
Lead Sponsor
Jazz Pharmaceuticals
Target Recruit Count
158
Registration Number
NCT00106860
Locations
🇺🇸

Midwest Clinical Research Center, Dayton, Ohio, United States

🇺🇸

IPS Research Company, Oklahoma City, Oklahoma, United States

🇺🇸

Oregon Center for Clinical Research, Inc., Eugene, Oregon, United States

and more 9 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy